Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ABBV crawled time : 13:15 save search
Buttock Augmentation Market Expected to Reach $11.2 Billion, Globally, by 2030 at 21.2% CAGR: Allied Market Research
Published: 2021-11-01 (Crawled : 13:15) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
ESTA | $47.425 -9.79% -10.85% 430K
|
Health Technology
|
| O: 0.16%
H: 1.63%
C: -0.36%
research
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)
Published: 2021-10-15 (Crawled : 13:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.22%
H: 0.74%
C: 0.16%
treatment europe positive risankizumab chmp
Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial
Published: 2021-10-05 (Crawled : 13:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.61%
H: 1.09%
C: 0.11%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.25%
H: 4.54%
C: 2.02%
positive results positive results trial
AbbVie to Host Third-Quarter 2021 Earnings Conference Call
Published: 2021-10-05 (Crawled : 13:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.61%
H: 1.09%
C: 0.11%
conference
AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease
Published: 2021-09-20 (Crawled : 13:15) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.33%
H: 1.31%
C: 0.28%
disease treatment fda risankizumab order
Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab
Published: 2021-09-15 (Crawled : 13:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.1%
H: 2.07%
C: 1.11%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: -2.29%
results phase 3
Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)
Published: 2021-06-04 (Crawled : 13:15) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.17%
H: 0.63%
C: -0.04%
leukemia
Migraines Be Gone: AbbVie’s Atopant Reduces Headache Frequency and Severity
Published: 2021-06-03 (Crawled : 13:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.25%
H: 1.16%
C: 0.98%
migraine
AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
Published: 2021-05-24 (Crawled : 13:15) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.4%
H: 0.19%
C: -0.58%
disease risankizumab
AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
Published: 2021-04-07 (Crawled : 13:15) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.14%
H: 0.57%
C: -0.3%
fda risankizumab ema application
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.